AUTL

Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in London, United Kingdom. The company specializes in developing engineered T-cell therapies for cancer treatment, with its lead product AUCATZYL receiving FDA approval in November 2024 for treating relapsed or refractory acute lymphoblastic leukemia (ALL) in adults. Autolus has evolved from a pure research and development company to a commercial-stage biotechnology firm with its own manufacturing capabilities and an expanding pipeline of cell therapy candidates targeting both hematological cancers and autoimmune diseases.